SEARCH

SEARCH BY CITATION

References

  • Brendel C, Scharenberg C, Dohse M, Robey RW, Bates SE, Shukla S et al. (2007). Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 21: 12671275.
  • Brozik A, Casey NP, Hegedus C, Bors A, Kozma A, Andrikovics H et al. (2006). Reduction of Bcr-Abl function leads to erythroid differentiation of K562 cells via downregulation of ERK. Ann N Y Acad Sci 1090: 344354.
  • Burger H, van Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G et al. (2004). Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 104: 29402942.
  • Dean M, Fojo T, Bates S (2005). Tumour stem cells and drug resistance. Nat Rev Cancer 5: 275284.
  • Deguchi Y, Kimura S, Ashihara E, Niwa T, Hodohara K, Fujiyama Y et al. (2008). Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Leuk Res 32: 980983.
  • Elkind NB, Szentpetery Z, Apati A, Ozvegy-Laczka C, Varady G, Ujhelly O et al. (2005). Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res 65: 17701777.
  • Giannoudis A, Davies A, Lucas CM, Harris RJ, Pirmohamed M, Clark RE (2008). Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood 112: 33483354.
  • Gottesman MM, Fojo T, Bates SE (2002). Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 4858.
  • Hamada A, Miyano H, Watanabe H, Saito H (2003). Interaction of imatinib mesilate with human P-glycoprotein. J Pharmacol Exp Ther 307: 824828.
  • Hazarika M, Jiang X, Liu Q, Lee SL, Ramchandani R, Garnett C et al. (2008). Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res 14: 53255331.
  • Hegedus T, Orfi L, Seprodi A, Varadi A, Sarkadi B, Keri G (2002). Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim Biophys Acta 1587: 318325.
  • Hiwase DK, Saunders V, Hewett D, Frede A, Zrim S, Dang P et al. (2008). Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res 14: 38813888.
  • Hollo Z, Homolya L, Davis CW, Sarkadi B (1994). Calcein accumulation as a fluorometric functional assay of the multidrug transporter. Biochim Biophys Acta 1191: 384388.
  • Hollo Z, Homolya L, Hegedus T, Sarkadi B (1996). Transport properties of the multidrug resistance-associated protein (MRP) in human tumour cells. FEBS Lett 383: 99104.
  • Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, Buchdunger E et al. (2004). Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 64: 23332337.
  • Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, Eaves A et al. (2007). Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 21: 926935.
  • Jordanides NE, Jorgensen HG, Holyoake TL, Mountford JC (2006). Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood 108: 13701373.
  • Jorgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL (2007). Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 109: 40164019.
  • Kim M, Turnquist H, Jackson J, Sgagias M, Yan Y, Gong M et al. (2002). The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. Clin Cancer Res 8: 2228.
  • Kotaki M, Motoji T, Takanashi M, Wang YH, Mizoguchi H (2003). Anti-proliferative effect of the abl tyrosine kinase inhibitor STI571 on the P-glycoprotein positive K562/ADM cell line. Cancer Lett 199: 6168.
  • Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J et al. (2003). MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101: 23682373.
  • Mahon FX, Hayette S, Lagarde V, Belloc F, Turcq B, Nicolini F et al. (2008). Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res 68: 98099816.
  • Nakanishi T, Shiozawa K, Hassel BA, Ross DD (2006). Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression. Blood 108: 678684.
  • Ozvegy C, Varadi A, Sarkadi B (2002). Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation. J Biol Chem 277: 4798047990.
  • Ozvegy-Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz JD, Varadi A et al. (2004). High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 65: 14851495.
  • Ozvegy-Laczka C, Laczko R, Hegedus C, Litman T, Varady G, Goda K et al. (2008). Interaction with the 5D3 monoclonal antibody is regulated by intramolecular rearrangements but not by covalent dimer formation of the human ABCG2 multidrug transporter. J Biol Chem 283: 2605926070.
  • Quintas-Cardama A, Kantarjian H, Cortes J (2007). Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 6: 834848.
  • Ren R (2005). Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 5: 172183.
  • Sarkadi B, Homolya L, Szakacs G, Varadi A (2006). Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev 86: 11791236.
  • Scharenberg CW, Harkey MA, Torok-Storb B (2002). The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 99: 507512.
  • Smeets M, Raymakers R, Vierwinden G, Pennings A, van de Locht L, Wessels H et al. (1997). A low but functionally significant MDR1 expression protects primitive haemopoietic progenitor cells from anthracycline toxicity. Br J Haematol 96: 346355.
  • Szakacs G, Varadi A, Ozvegy-Laczka C, Sarkadi B (2008). The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov Today 13: 379393.
  • Telbisz A, Muller M, Ozvegy-Laczka C, Homolya L, Szente L, Varadi A et al. (2007). Membrane cholesterol selectively modulates the activity of the human ABCG2 multidrug transporter. Biochim Biophys Acta 1768: 26982713.
  • Thomas J, Wang L, Clark RE, Pirmohamed M (2004). Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104: 37393745.
  • Weisberg E, Catley L, Wright RD, Moreno D, Banerji L, Ray A et al. (2007a). Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood 109: 21122120.
  • Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD (2007b). Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 7: 345356.
  • White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC et al. (2006). OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108: 697704.
  • White DL, Saunders VA, Quinn SR, Manley PW, Hughes TP (2007). Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs. Blood 109: 36093610.
  • Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ et al. (2001). The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 7: 10281034.